Interleukin 5 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid in interstitial lung disease


ABSTRACT: The purpose of this study was to evaluate the role of several eosinophil growth factors including interleukin (IL)-5, interleukin (IL)-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) in the pathogenesis of interstitial lung disease with eosinophilia.

IL-5, IL-3 and GM-CSF in bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA) in patients with eosinophilic pneumonia (EP), bronchiolitis obliterans organizing pneumonia (BOOP), idiopathic pulmonary fibrosis (IPF), sarcoidosis and healthy volunteers.

IL-5 in BALF was high only in patients with EP. IL-3 in BALF was undetectable in the majority of patients with these diseases. GM-CSF in BALF was detectable in 30–67% of each group of patients. In patients with BOOP and IPF, the number of eosinophils in BALF was higher in patients with detectable GM-CSF than in patients in whom GM-CSF was below the detection limit. Eosinophil cationic protein (ECP) was detected in all patients with EP and some with BOOP and IPF. There was a significant correlation between ECP levels and percentage or number of eosinophils in BALF.

The results suggest the possibility that interleukin 5 in eosinophilic pneumonia and granulocyte-macrophage colony-stimulating factor in bronchiolitis obliterans organizing pneumonia and idiopathic pulmonary fibrosis may play important roles in eosinophil recruitment in the lung. Activation of eosinophils in the lung is likely to be induced by both interleukin 5 and granulocyte-macrophage colony-stimulating factor.


Interleukin (IL)-5, interleukin (IL)-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) are eosinophil growth factors as reported by many investigators [1–3]. In addition, IL-5 has also been studied as a growth and differentiation factor for B lymphocytes and eosinophils [4–6] although in humans, it is thought to act mainly on eosinophils. It has been reported that human IL-5 stimulates the function of mature eosinophils and is a potent and selective chemoattractant for eosinophils [4, 7]. Since eosinophils are localized in tissues under a variety of physiological and pathological conditions, locally produced IL-5 may play a role in the selective recruitment of eosinophils from the peripheral circulation. It has been also shown that IL-5 plays an important role in lung eosinophilia in mice by using an anti-IL-5 monoclonal antibody, IL-5-deficient mice and IL-5 receptor α-deficient mice [8–10]. The effects of IL-3 and GM-CSF on eosinophils are similar to those of IL-5 [11, 12]. Bronchoalveolar lavage fluid (BALF) of patients with certain interstitial lung diseases (ILDs), such as eosinophilic pneumonia (EP), bronchiolitis obliterans organizing pneumonia (BOOP), and idiopathic pulmonary fibrosis (IPF) [13–15], contains a high number of eosinophils and elevated levels of IL-5 and GM-CSF [16]. In addition, IL-3 is a growth and survival factor for multipotent haematopoietic stem cells and activates not only eosinophils but also macrophages and natural killer (NK) cells [2]. On the other hand, GM-CSF stimulates the generation of leukocyte precursors, such as monocytes, neutrophils and eosinophils, and activates antigen presenting cells [1].

Eosinophil cationic protein (ECP) are also elevated in the bronchoalveolar lavage fluid of patients with ILD such as IPF and EP and there is a significant relationship between the number of eosinophils and ECP levels in BALF of such patients [13, 14]. Although the exact aetiology of these diseases is unknown, accumulation of eosinophils in the lung is thought to be one component of the pathogenesis of these disorders since ECP is a cytotoxic substance and the presence of high concentrations of ECP in BALF of patients with IPF and EP indicates activation of eosinophils in the lung [17].

In this study, the concentrations of IL-5, IL-3 and GM-CSF in BALF of patients with ILD and healthy subjects...
was measured to evaluate the role of these cytokines in eosinophil recruitment into the lung in eosinophilic lung disease. The relationship between each cytokine and eosinophils recovered from BALF was investigated, and the ECP concentrations in BALF in these diseases as a marker of degranulation of activated eosinophils was measured.

Materials and methods

Patient population

Included in this study were nine untreated patients with EP (6 females and 3 males, aged 42.8±16.8 yrs), 16 with BOOP (11 females and 5 males, aged 63.3±11.3 yrs), 14 with IPF (3 females and 11 males, aged 63.1±6.3 yrs) and 17 with sarcoidosis (13 females and 4 males, aged 45.7±5.1 yrs), who were referred to the Miyazaki Medical College Hospital (Miyazaki, Japan) and Nagasaki University hospital, as well as 14 healthy adult volunteers (3 females and 11 males, aged 24.8±4.2 yrs). None of the patients with ILDs in this study were treated with corticosteroids. At the time of the investigation, one patient with EP, three with BOOP, six with IPF, four with sarcoidosis and no volunteers were smokers.

The diagnosis of EP was based on clinical criteria; patients with no known cause of EP (drugs, parasitic infection and fungal disease), with acute or chronic dyspnoea, interstitial infiltrates on chest radiographs, pulmonary eosinophilia, and prompt resolution of clinical and radiographic abnormalities with or without corticosteroid therapy. All patients showed peripheral eosinophilia. The diagnosis of BOOP was based on clinicopathologic evaluation as following: 1) consistent clinical history and radiographic findings (chest roentgenograms showed alveolar, interstitial or mixed opacities), as described [18]; 2) typical histologic pattern of BOOP at transbronchial biopsy (in three patients by open lung biopsy); 3) no evidence of any underlying disorder or known aetiology of BOOP, and blood eosinophilia; 4) rapid response to corticosteroid treatment.

The diagnosis of IPF was based on the following criteria: 1) no clinical history of exposure to environmental agents known to cause interstitial lung disease; 2) no history of chronic lung infections; 3) evidence of interstitial infiltrates on chest roentgenogram and chest CT scan; 4) pulmonary function test with restrictive ventilatory defect; and 5) histologic evidence of interstitial pneumonitis with varying degrees of interstitial fibrosis without granulomas. The diagnosis of sarcoidosis was made by examination of biopsy specimens obtained from lungs, lymph nodes, or skin showing noncaseating epithelioid cell granulomas, with no evidence of inorganic material known to cause granulomatous diseases.

Bronchoalveolar lavage

After obtaining informed written consent from the subject, BAL was performed using a flexible fibreoptic bronchoscope (Olympus BF-P20; Olympus, Tokyo, Japan) under local anaesthesia of the upper airway with 2% lidocaine as described previously [19]. The bronchoscope was wedged into the subsegmental bronchus of the right middle lobe or, in patients with EP and BOOP, into areas of lung parenchyma otherwise normal on chest roentgenogram, and 150 or 200 mL normal saline was instilled in 50 mL aliquots. BAL fluid was filtered through sterile nylon mesh and centrifuged at 160 × g for 2 min to obtain the cell preparation. The cells were later stained by the May-Giemsa method and a differential count was performed on 200 cells. The remaining fluid was centrifuged at 500 × g for 5 min and the supernatant stored at -80°C until use.

Measurement of interleukin 5 and 3, granulocyte-macrophage colony-stimulating factor and eosinophil cationic protein in bronchoalveolar lavage fluid

IL-5 was measured using an enzyme-linked immunosorbent assay (ELISA). Briefly, 50 μL monoclonal antibody to human IL-5 (TRFK5; Pharmingen, San Diego, CA, USA) (4 μg·mL⁻¹) was bound to microtiter plates by incubating at 4°C overnight. The wells were washed twice with phosphate-buffered saline (PBS) containing 0.05% Tween 20. After blocking with 400 μL PBS/10% foetal calf serum for 2 h, 100 μL BAL supernatant and recombinant human IL-5 (Pharmingen) were added to each well and incubated at 4°C overnight. After washing twice with 0.05% Tween/PBS, 100 μL secondary antibody (biotinylated anti-human IL-5 monoclonal antibody (JES1-SA10; Pharmingen)) (4 μg·mL⁻¹) was added to each well and incubated at room temperature for 1 h, followed by further 1 h incubation with 100 μL of peroxidase conjugated streptavidin. Wells were subsequently washed 5 times with 0.05% Tween/PBS and incubated with 0.11 M sodium acetate buffer (pH 5.5) containing tetramethylbenzidine for 15 min or until a suitable colour developed. The reaction was stopped by adding 100 μL 1.8 M H₂SO₄ to each well. Absorbance of the plates was read at 450 nm in an ELISA reader. The assay was linear over the range of approximately 20–680 pg·mL⁻¹ and was specific for IL-5 without cross-reactivity to recombinant IL-3 or GM-CSF. The average level from duplicate assays was obtained. IL-3 and GM-CSF were measured using an ELISA kit (R&D systems, Minneapolis, USA). The detection limits were 20.0, 31.2, 3.9 pg·mL⁻¹ for IL-5, IL-3 and GM-CSF, respectively. ECP was measured using an ECP radioimmunoassay (RIA) kit (Pharmacia Diagnostics, Uppsala, Sweden). The detection limit of ECP was 2 μg·L⁻¹. Concentrations below the lower limit of detection were assumed to be zero for the purpose of statistical analysis. The absolute values of cytokines were reported in this study, because the level of the cytokines was not influenced by the concentration of albumin in a previous study carried out by the authors [20].

Statistical analysis

All data are expressed as mean±standard deviation (SD). Statistical comparisons were performed by the Mann-Whitney U-test to examine differences between the means of unpaired samples. The Spearman’s rank correlation was used to examine the relationship between parameters. Significance was defined as p<0.05.
Results

Characteristics of bronchoalveolar lavage fluid cells

The total number and differential count of leukocytes in BALF are summarized in table 1. The total number of cells/mL of BALF in all patient groups was higher than that in healthy subjects. In the differential cell count, the percentage/absolute number of eosinophils in EP (p<0.01/0.01) and IPF (p<0.05/0.01) was significantly higher than in control subjects, while the per cent of eosinophils in sarcoïdosis was not increased. The absolute number of eosinophils was increased in patients with BOOP compared with healthy volunteers, but the difference was not significant (table 1). The percentage of lymphocytes was significantly higher in patients with BOOP (p<0.01) and sarcoïdosis (p<0.05) than in healthy subjects. The percentage of neutrophils in the EP (p<0.05), BOOP (p<0.05), and IPF (p<0.01) patients was significantly higher than in controls.

Interleukin 5, 3 and granulocyte-macrophage colony-stimulating factor levels in bronchoalveolar lavage fluid

Interestingly, IL-5 was detected only in patients with EP. Furthermore, follow-up lavages were performed in three of the nine patients with EP after treatment with corticosteroids, IL-5 was not detected in any follow-up lavage (data not shown). Although the number of eosinophils was high in patients with BOOP and IPF, IL-5 was not detected in any patient with these diseases (fig. 1). Furthermore, IL-5 in BALF was below the detection limit in healthy subjects and patients with sarcoïdosis. IL-3 was detected in two of the six patients with EP and one of the 13 with BOOP (fig. 2a) while GM-CSF was detected in four of the nine patients with EP and three of the 10 with both BOOP and IPF (fig. 2b). IL-3 and GM-CSF were not detected in BALF of all healthy subjects. There were no significant differences in cytokine (IL-5, IL-3, GM-CSF) levels of BALF between smokers and nonsmokers in each disease.

Relationship between eosinophilia and granulocyte-macrophage colony-stimulating factor in bronchoalveolar lavage fluid

To evaluate the role of GM-CSF in EP, BOOP and IPF, patients were divided into two groups depending on the level of GM-CSF in BALF (below or above the detection limit; 3.9 pg·mL⁻¹). In patients with BOOP and IPF, the absolute number of eosinophils in BALF was significantly higher in GM-CSF-detectable groups compared with GM-CSF-undetectable groups (p<0.05). In patients with EP, however, the absolute number of eosinophils was not significantly different between the two groups (fig. 3). Because GM-CSF is also a growth and differentiation factor of neutrophils, the absolute numbers of neutrophils in BALF of these patients were also compared. There was no relationship between lung neutrophilia and GM-CSF levels in BALF (fig. 3b).

Eosinophil cationic protein concentration in bronchoalveolar lavage fluid

The concentration of ECP in BALF was evaluated in patients with lung eosinophilia. ECP was detected in all patients with EP, one of the 12 patients with BOOP and five of the 14 with IPF (fig. 4a). Furthermore, there was a significant correlation between ECP concentration and percentage of eosinophils (r=0.533, p<0.01) (fig. 4b) or absolute eosinophil numbers (r=0.392, p<0.01) in BALF.

Discussion

The major findings of the present study were that IL-5 and GM-CSF could be involved in the recruitment of eosinophils into the lung in patients with certain ILDs.

Table 1. Characteristics of bronchoalveolar lavage fluid cells in interstitial lung disease

<table>
<thead>
<tr>
<th></th>
<th>Volume recovered</th>
<th>Total cells</th>
<th>Macrophages</th>
<th>Lymphocytes</th>
<th>Neutrophils</th>
<th>Eosinophils</th>
<th>Eosinophils</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>10⁵·mL⁻¹</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>%</td>
<td>10¹·mL⁻¹</td>
</tr>
<tr>
<td>HV</td>
<td>64.5±9.7</td>
<td>1.5±0.7</td>
<td>87.3±6.9</td>
<td>10.1±6.0</td>
<td>1.7±3.6</td>
<td>0.9±2.0</td>
<td>1.6±3.9</td>
</tr>
<tr>
<td>EP</td>
<td>42.9±23.6*</td>
<td>8.0±6.6**</td>
<td>23.4±14.0**</td>
<td>19.0±13.0</td>
<td>9.1±12.5**</td>
<td>47.6±23.4**</td>
<td>460.9±575.6**</td>
</tr>
<tr>
<td>BOOP</td>
<td>44.5±14.9**</td>
<td>10.4±19.7</td>
<td>50.8±30.5**</td>
<td>29.5±24.0*</td>
<td>14.7±27.7**</td>
<td>1.3±1.7</td>
<td>7.1±11.0</td>
</tr>
<tr>
<td>IPF</td>
<td>41.1±14.9**</td>
<td>4.4±2.9**</td>
<td>66.7±22.6**</td>
<td>17.9±18.1</td>
<td>10.3±11.4**</td>
<td>5.0±7.3**</td>
<td>27.0±60.0**</td>
</tr>
<tr>
<td>Sar</td>
<td>58.4±11.8</td>
<td>3.1±2.2*</td>
<td>58.2±22.7**</td>
<td>39.8±21.6**</td>
<td>1.6±2.2</td>
<td>0.5±0.9**</td>
<td>4.4±12.3</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD. *: p<0.05; **: p<0.01; both compared with healthy volunteer subjects. HV: healthy volunteer subjects (n=14); EP: eosinophilic pneumonia (n=9); BOOP: bronchiolitis obliterans organizing pneumonia (n=16); IPF: idiopathic pulmonary fibrosis (n=14); Sar: sarcoïdosis (n=17).
ECP is a cytotoxic component of eosinophil granules [21–23]. In this study, a correlation between increased ECP levels and eosinophilia in BALF was demonstrated. It has previously been reported that ECP levels in BALF were correlated with the eosinophil numbers in BALF of patients with EP and IPF [14, 24, 25]. These findings appear to reflect local secretion and/or leakage of ECP by activated eosinophils.

IL-5, IL-3 and GM-CSF are proliferation, differentiation and activation factors of eosinophils [3, 26, 27]. IL-5 especially promotes the terminal differentiation of eosinophil progenitors in human bone marrow [26, 27] and is a selective activator of mature eosinophils in humans [4, 5]. As previously reported by Ochiai et al. [28], the BALF of two EP patients in the present study also increased the survival rate of eosinophils in vitro, and that effect on eosinophils was completely blocked by addition of anti-IL-5 monoclonal antibody (data not shown). Furthermore, previous studies have demonstrated that elevated IL-5 was detected in BALF and serum from patients with symptomatic, but not asymptomatic asthma [29, 30]. These studies suggested that IL-5 may become detectable as asthma progresses to a symptomatic state. However, there have been only a few detailed reports demonstrating that high IL-5 levels were detected in BALF from ILD [16, 31]. In the present study, IL-5 was detected only in BALF of patients with EP. This finding is inconsistent with those reported earlier by Walker et al. [16] who demonstrated elevated IL-5 in both EP and IPF. In their study, IL-5 levels in EP were only a few times higher than those in IPF, whereas in this present study, extremely high levels of IL-5 were detected in EP compared with IPF. This discrepancy may result from the use of a different methodology. Walker et al. [16] used concentrated BALF in proliferation assays using a cytokine-specific cell line, which may reflect cytokine activity, while protein concentration was measured with the ELISA method in this study. Furthermore, both acute and chronic EP were included in patients with EP which were examined in the present study. These may explain the finding that IL-5 concentration in BALF did not
Inhibition of IL-5 production may be a potential specific role in pulmonary eosinophilia in patients with EP. These observations indicate that IL-5 may play an important role in BALF of EP patients (data not shown). Nevertheless, correlate with the percentage and number of eosinophils in BALF from all patients (r=0.533, p<0.01).

IL-3 and GM-CSF have pronounced effects on eosinophils, but their functions are not selective to eosinophils [29]. In this study, IL-3 was undetectable in BALF in the majority of patients (23 of the 26), suggesting that it is unlikely to be involved in the pathogenesis of ILD. On the other hand, detectable levels of GM-CSF were present in BALF in 4 of the 9 EP patients (44.4%) and in 3 of the 10 patients with both BOOP and IPF (30%). Although GM-CSF was detected in a low number of patients, eosinophil numbers in BALF were significantly higher in GM-CSF-detectable groups than GM-CSF-undetectable groups of BOOP and IPF patients (fig. 3a). These findings suggest that GM-CSF could in part contribute to lung eosinophilia in patients with BOOP and IPF, and also suggest the possibility that different eosinophil growth factors might cause lung eosinophilia in various eosinophilic lung diseases. The authors have previously reported that different subpopulations of T cells, CD4+ human leukocyte antigen (HLA)-DR+ cells and CD8+HLA-DR+ cells, in BALF were increased in EP and BOOP respectively [32].

To conclude it has been demonstrated that interleukin 5 may play an important role in the pathogenesis of eosinophil infiltration in the lung in patients with eosinophilic pneumonia. Further studies are necessary to elucidate the cytokine-producing cells and the stimulatory mechanisms of cytokine production in different eosinophilic lung diseases.

Acknowledgements. The authors would like to thank K. Takatsu and Y. Kikuchi for technical advice regarding the interleukin 5 enzyme-linked immunosorbent assay, and A. Yokoyama for technical assistance.

References


